Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Neurocrine Biosciences, Inc.    NBIX

NEUROCRINE BIOSCIENCES, INC. (NBIX)
My previous session
Most popular
  Report  
Delayed Quote. Delayed  - 12/14 10:00:03 pm
71.34 USD   -2.29%
2015Wall St. jumps for second day, helped by economic optimism
RE
2013NEUROCRINE BIOSCIENCES, INC. : quaterly earnings release
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/10/2018 12/11/2018 12/12/2018 12/13/2018 12/14/2018 Date
85.81(c) 85.76(c) 73.83(c) 73.01(c) 71.34(c) Last
571 199 508 886 13 083 465 2 415 550 1 360 938 Volume
+1.94% -0.06% -13.91% -1.11% -2.29% Change
More quotes
Financials (USD)
Sales 2018 448 M
EBIT 2018 30,0 M
Net income 2018 12,3 M
Finance 2018 474 M
Yield 2018 -
Sales 2019 636 M
EBIT 2019 176 M
Net income 2019 140 M
Finance 2019 505 M
Yield 2019 -
P/E ratio 2018 496,80
P/E ratio 2019 44,51
EV / Sales2018 13,4x
EV / Sales2019 9,37x
Capitalization 6 469 M
More Financials
Company
Neurocrine Biosciences, Inc. is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are... 
More about the company
Surperformance© ratings of Neurocrine Biosciences, In
Trading Rating : Investor Rating :
More Ratings
Latest news on NEUROCRINE BIOSCIENCES, IN
12/15NEUROCRINE BIOSCIENCES : slumps as Tourettes drug fails clinical trial
AQ
12/14NEUROCRINE BIOSCIENCES : Announces Topline Data from Phase IIb T-Force GOLD Stud..
AQ
12/13NEUROCRINE BIOSCIENCES : Announces Topline Data from Phase IIb T-Force GOLD Stud..
AQ
12/12NEUROCRINE BIOSCIENCES : down on Phase IIb Tourette syndrome miss
AQ
12/12NEUROCRINE BIOSCIENCES INC : Other Events, Financial Statements and Exhibits (fo..
AQ
12/12NEUROCRINE BIOSCIENCES : Announces Topline Data from Phase IIb T-Force GOLD Stud..
PR
11/16ABBVIE : Presents Positive Phase 3 Data Demonstrating Investigational Elagolix R..
AQ
11/07NEUROCRINE BIOSCIENCES : to Present at the Jefferies 2018 London Healthcare Conf..
PR
11/05NEUROCRINE BIOSCIENCES INC : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL C..
AQ
11/05NEUROCRINE : 3Q Earnings Snapshot
AQ
More news
Analyst Recommendations on NEUROCRINE BIOSCIENCES, IN
More recommendations
Sector news : Bio Therapeutic Drugs
12/14FDA Approves Herceptin Biosimilar Herzuma
DJ
12/13Lilly, Incyte Get FDA Fast-Track Designation for Baricitinib in Systemic Lupu..
DJ
12/10Almost half of S&P 500 stocks in a bear market
RE
12/10ROCHE : Gilead Sciences snares Roche veteran O'Day as CEO
RE
12/10LONZA : to Establish Biomanufacturing Base in China
DJ
More sector news : Bio Therapeutic Drugs
Chart NEUROCRINE BIOSCIENCES, INC.
Duration : Period :
Neurocrine Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NEUROCRINE BIOSCIENCES, IN
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 109 $
Spread / Average Target 52%
EPS Revisions
Managers
NameTitle
Kevin Charles Gorman Chief Executive Officer & Director
William H. Rastetter Chairman
Matthew C. Abernethy Chief Financial Officer
Dimitri E. Grigoriadis Chief Research Officer
Bill Wilson Vice President-Information Technology & Operations
Sector and Competitors
1st jan.Capitalization (M$)
NEUROCRINE BIOSCIENCES, INC.-8.06%6 469
GILEAD SCIENCES-8.47%84 823
VERTEX PHARMACEUTICALS15.72%43 460
REGENERON PHARMACEUTICALS1.39%40 527
GENMAB3.84%9 952
SAREPTA THERAPEUTICS INC114.81%7 987